Results 81 to 90 of about 204,163 (273)

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma [PDF]

, 2016
Key Points Combining phosphatidylinositol-3-kinase δ inhibition with rituximab, bendamustine, or both is feasible and active in relapsed iNHL.
Barrientos, Jacqueline C., Boccia, Ralph V., Boyd, Thomas E., Coutre, Steven E., de Vos, Sven, Flinn, Ian W., Fowler, Nathan H., Furman, Richard R., Godfrey, Wayne R., Kim, Yeonhee, Leonard, John P., Rai, Kanti R., Schreeder, Marshall T., Sharman, Jeff P., Wagner-Johnston, Nina D.   +14 more
core   +2 more sources

Non‐Cancer Causes of Death in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Analysis

The Prostate, EarlyView.
ABSTRACT Background As overall survival improves in metastatic hormone‐sensitive prostate cancer (mHSPC), non‐cancer causes of death are increasingly relevant. Methods We conducted a real‐world multicenter study of patients diagnosed with mHSPC treated with ADT alone or in combination. Causes of death before progression to castration‐resistant prostate
Marta Garcia de Herreros, Clara Rodrigo, Laura Ferrer‐Mileo, Laia Fernández‐Mañas, Joel Mases, Nely Diaz, Antoni Vilaseca, Mariana Altamirano, Roser Gibanel, Maria José Ribal, Natalia Jimenez, Oscar Reig, Mariona Figols, Miguel Ángel Climent, Albert Font, Begoña Mellado   +15 more
wiley   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia

Advances in Therapy, 2018
IntroductionShort- and long-acting granulocyte-colony stimulating factors (G-CSFs) are approved for the reduction of febrile neutropenia. A systematic literature review was performed to identify randomized controlled trials (RCTs) and non-RCTs reporting ...
P. Cornes, P. Gascón, S. Chan, K. Hameed, Catherine R Mitchell, P. Field, M. Latymer, Luiz H Arantes   +7 more
semanticscholar   +1 more source

A de-escalation protocol for febrile neutropenia cases and its impact on carbapenem resistance: A retrospective, quasi-experimental single-center study

Journal of Infection and Public Health, 2016
Our objective was to evaluate the impact of using an imipenem de-escalation protocol for empiric febrile neutropenia on the development of carbapenem resistance.A pre-post intervention design was used.
Abeer Alshukairi, Haleema Alserehi, Aiman El-Saed, Mouhammed Kelta, Jalil U. Rehman, Farrukh A. Khan, Hanadi Alsalmi, Majda Alattas, Muhammad Aslam   +8 more
doaj   +1 more source

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations

Supportive Care in Cancer, 2017
PurposeChemotherapy-induced febrile neutropenia (FN) causes treatment delays and interruptions and can have fatal consequences. Current guidelines provide recommendations on granulocyte colony-stimulating factors (G-CSF) for prevention of FN, but ...
M. Aapro, R. Boccia, R. Leonard, C. Camps, M. Campone, S. Choquet, M. Danova, J. Glaspy, I. Hus, H. Link, T. Sliwa, H. Tesch, V. Valero   +12 more
semanticscholar   +1 more source

Neutropenia febril

Revista Española de Casos Clínicos en Medicina Interna, 2020
La quimioterapia deprime la mielopoyesis y afecta a la integridad de las mucosas gastrointestinales aumentando el riesgo de infecciones sistémicas por translocación de bacterias y hongos. La neutropenia febril es una complicación grave cuya tasa de mortalidad es de hasta el 11%.
María Mar Cutillas-Pérez, Cristina Macía-Rodríguez, Lucía Santomé-Couto, Javier de la Fuente-Aguado   +3 more
openaire   +1 more source

Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom

British Journal of Haematology, EarlyView.
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group   +35 more
wiley   +1 more source

Chemotherapy Induced Neutropenia, Febrile-Neutropenia and Determinants Among Solid Cancer Patients Attending Oncology Unit of a Tertiary Care Teaching Hospital in Ethiopia

Cancer Management and Research, 2023
Mekonnen Dessalegn,1,2 Mengistu Fantahun,2 Abdu Adem Yesufe,2 Mintewab Hussein,1 Aster Tsegaye1 1Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; 2St Paul’s Hospital Millennium Medical ...
Dessalegn M, Fantahun M, Yesufe AA, Hussein M, Tsegaye A   +4 more
doaj  

Malnutrition is a predisposing factor for developing recurrent fever following febrile neutropenia in children with acute lymphoblastic leukemia

Pediatric Hematology Oncology Journal, 2020
Introduction: The factors that predict recurrence of fever following defervescence (DS) during febrile neutropenia (FN) episode have not been studied. The objective was to estimate the incidence and risk factors for recurrent fever (RF) in children with ...
Jaikumar Govindaswamy Ramamoorthy, Venkatraman Radhakrishnan, Prasanth Ganesan, Manikandan Dhanushkodi, T.S. Ganesan, T.G. Sagar   +5 more
doaj   +1 more source